

Access • Education • Hope



The Oncidium foundation focuses on raising awareness about Radiotheranostics as an alternative for cancer therapy and providing support to accelerate global access.

Oncidium leads the way in this patient-focused science, by raising funds to advance the availability of Radiotherapeutic technologies and facilitate worldwide access to patients.

WHO WE ARE

We are motivated to help people live longer and better lives. The patients are the core focus of Oncidium's activity by accelerating global access to this precision medicine.

> The Oncidium foundation team is fully dedicated to promoting the development of nuclear medicine therapy. To this day, many patients and non-nuclear practitioners are still unaware of the existence and benefits of Radiotheranostics for cancer treatments.

As a non-profit and public benefit organization, the Oncidium foundation is independant, hence allowing to solely focus on reaching out to patients and other interlocutors about this innovating and lifesaving technology.

Richard Zimmermann, Tala Allahham, Rebecca Lo bue, Floriane Laurent



Frogresses made in Radionuclide Theranostics over the last few years have shown incredible results.

My main wish with this new team is to make this technology available for the largest number of patients.

Richard Zimmermann Founder & President The Oncidium foundation

PROMOTING RADIOTHERANOSTICS



ACCESS

The key element of The Oncidium foundation is to make Radiotheranostics available for as many people as possible. Therefore, efforts are concentrated towards improving access to cancer treatments and clinical trials.

An effective platform through our website is implemented for:

PATIENTS to find the nearest center and to communicate directly with medical experts

PRACTITIONERS to offer the best treatment available

Radiotheranostics **EXPERTS** to help promote precision medicine and its progresses.

The Oncidium foundation is presently evaluating all possibilities to **financially support** individual cases to reduce treatments overall costs in low income countries. The Oncidium foundation is a worldwide hub connecting patients, practitioners and experts in the nuclear medicine field.

EDUCATION

Education and Awareness are essential to promote precision medicine, as it helps bring a better understanding of the functioning and benefits of Radiotheranostics for cancer therapy.

Moreover, the foundation will deal with the common stereotypes around nuclear medicine and its impact on human health. Education is focused on:

PATIENTS: by explaining how Radiotheranostics could be in some cases the best solutions to some cancer treatments

PRACTITIONERS: by helping them take note and keep track of developments around Radiotheranostics.

HOPE

The Oncidium foundation is driven by the long-term vision of improving lives globally. Common efforts and working hand in hand are essential to provide Hope:

- For patients, when "conventional cure" is not an option
- For patients, that are not able to afford the therapy costs
- To support and finance the **development of radiopharmaceuticals for therapy**, focusing primarily on drugs that are not supported by industry, i.e. drugs with expired patents or generics, orphan drugs or drugs for small markets, and drugs for treatment of diseases with a high prevalence in developing countries.

RADIOTHERANOSTICS: HOW DOES IT WORK?

Radiopharmaceuticals are molecules developed as diagnostic and/or therapeutic agents based on drugs labeled with radioactive atoms and injected into patients. When these molecules are developed as pairs for diagnosis and therapy in the same disease, they are called Radiotheranostic pairs.



Its role?

Precisely target a biological entity that

is specific for one tissue, one type of cell or one organ (e.g. a tumor cell).

What's what?

- For each pathology, specific ligands can be associated with receptors from the targeted cells.
- This ligand can be converted in a vector that will carry a radioactive atom to this target.

Usage?

Depending on the type of emitted radiation (rays or particles) the atom (radionuclide) will act as:

- A tracer, i.e. an imaging (diagnosis) agent emitting a signal from the target-bound tissue OR
- A drug, i.e. a therapeutic agent destroying the targeted cells.



SUCCESS STORY

In the battle against metastatic prostate cancer, studies have demonstrated a high response rate to radionuclide therapy targeting prostate specific membrane antigen (PSMA) with the radionuclide lutetium-177 (¹⁷⁷Lu).

The images below which received the 2018 Image of the Year award from SNMMI come from a team of researchers at the Peter MacCallum Cancer Centre in Melbourne, Australia. They demonstrate exceptional responses in a series of patients who received LuPSMA therapy after other treatments stopped working. In each patient, the extent of tumor spread before and after treatment is visualized with clarity using PSMA PET. These patients experienced improved quality of life, including reduction of pain correlated with marked reduction of prostate specific antigen (PSA), a blood tumor marker.



Image used with permission of Prof. Michael Hofman, Peter MacCallum Cancer Centre, Melbourne, Australia

Aims of the foundation:

- Increase awareness about the use of Radiotheranostics among patients and practitioners
- Invest in research and scholarships to further develop the field
- Facilitate access for patients to this innovative and life-saving technology.

Supported by :





`itm









Contact us:

The Oncidium foundation Avenue Herrmann Debroux 40 1160 Brussels | Belgium www.oncidiumfoundation.org contact@oncidium-life.org



Be of help:

- Become local contacts
- Register your therapy center
- Join our network and... Spread the word!

